Please enable JS

NEJM Study of Evolocumab Efficacy in Lowering LDL Cholesterol

12/ 26

ARTICLE DETAILS

AUTHOR: 50SN Staff

DATE: Dec 26, 2017

TAGS:

SHARE ON: Twitter - Facebook - LinkedIn

NEJM Study of Evolocumab Efficacy in Lowering LDL Cholesterol

A study published in the New England Journal of Medicine found that Repatha® (evolocumab) reduced LDL cholesterol levels by 61 percent from pretreatment levels, and this reduction was sustained through 48 weeks. Patients taking evolocumab also showed a reduction in the rate of cardiovascular events. Learn more about the differences among LDL, HDL and triglycerides from the American Heart Association.

Read more.


 

Font Resize